PROQR THRAPEUTICS N V's ticker is PRQR and the CUSIP is N71542109. A total of 48 filers reported holding PROQR THRAPEUTICS N V in Q4 2020. The put-call ratio across all filers is 13.85 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $669,000 | -18.7% | 899,257 | -15.0% | 0.00% | 0.0% |
| Q2 2022 | $823,000 | -17.7% | 1,058,091 | -4.3% | 0.00% | 0.0% |
| Q1 2022 | $1,000,000 | -87.8% | 1,105,093 | +7.9% | 0.00% | -87.5% |
| Q4 2021 | $8,201,000 | -18.7% | 1,023,825 | -15.1% | 0.01% | -27.3% |
| Q3 2021 | $10,092,000 | +45.7% | 1,205,760 | +17.3% | 0.01% | +57.1% |
| Q2 2021 | $6,927,000 | +59.4% | 1,027,802 | +56.3% | 0.01% | +40.0% |
| Q1 2021 | $4,346,000 | +212.4% | 657,462 | +98.5% | 0.01% | +150.0% |
| Q4 2020 | $1,391,000 | -12.3% | 331,204 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $1,586,000 | +36.1% | 331,204 | +72.8% | 0.00% | 0.0% |
| Q2 2020 | $1,165,000 | +167.8% | 191,614 | +141.8% | 0.00% | +100.0% |
| Q1 2020 | $435,000 | -16.0% | 79,242 | +51.7% | 0.00% | 0.0% |
| Q4 2019 | $518,000 | +123.3% | 52,224 | +29.9% | 0.00% | – |
| Q3 2019 | $232,000 | – | 40,215 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| M28 Capital Management LP | 1,910,600 | $2,483,780 | 2.85% |
| Privium Fund Management B.V. | 5,344,446 | $6,947,780 | 2.07% |
| DAFNA Capital Management LLC | 940,582 | $1,222,757 | 0.38% |
| Monaco Asset Management SAM | 377,517 | $490,772 | 0.15% |
| EcoR1 Capital, LLC | 2,980,016 | $3,874,021 | 0.13% |
| Ikarian Capital, LLC | 472,625 | $614,412 | 0.07% |
| FRANKLIN STREET ADVISORS INC /NC | 150,000 | $195 | 0.02% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 3,625,467 | $4,713,107 | 0.01% |
| GSA CAPITAL PARTNERS LLP | 74,084 | $96 | 0.01% |
| UBS OCONNOR LLC | 189,328 | $246,126 | 0.01% |